The Globe and Mail reports in its Friday edition that TD Cowen analyst Michael Tupholme is sticking with his "buy" call on Nutrien. The Globe's David Leeder writes that Mr. Tupholme gave his share target a $3 boost to $70 (all figures U.S.). Analysts on average target the shares at $65.96. Mr. Tupholme is now projecting adjusted earnings before interest, taxes, depreciation and amortization for Nutrien's second quarter of $2.25-billion, which is a flat reading year-over-year (at $2.23-billion in fiscal 2024) and narrowly below the Street's expectation of $2.32-billion. He thinks gains in the retail and potash segments are likely to be offset by declines in nitrogen and phosphate. Mr. Tupholme says in a note: "We are not expecting any notable changes to Nutrien's 2025 guidance as part of second quarter results release. That said, we will be looking for updated market outlook commentary from management regarding fertilizer demand and pricing expectations. Our full-year 2025 adjusted EBITDA estimate of $5.86-billion compares to consensus of $5.737-billion. We see NTR as positioned to grow its retail EBITDA and fertilizer sales volumes over our forecast period. ... Further, we view Nutrien as offering attractive value."